European Pharmacovigilance Congress 2024
![](https://www.pharmaeducationcenter.it/wp-content/themes/pec-child/img/flags/en.png)
![](https://www.pharmaeducationcenter.it/wp-content/themes/pec-child/img/flags/en.png)
Panoramica della conferenza
The European Pharmacovigilance Congress, organized by Pharma Education Center, is recognized as one of the most important and appreciated global pharmacovigilance conferences.
EUPV congress is proud to have high quality scientific content as its main characteristic which has attracted growing interest from speakers, sponsors and participants from all over the world.
The EUPV congress gathers PV professionals at all career levels, including key decision makers (e.g. VPs, Executives and Directors,) interested in the always evolving pharmacovigilance world and its new trends, since they are always looking for new ideas to implement more efficient and effective strategies and tools for their departments.
To further improve the value of the congress and continuously make it more and more interesting by bringing new ideas and scientific contents, this year the Scientific Advisory Group has been further widened with the addition of new PV key opinion leaders who need no introduction since their knowledge and skills are world class.
EUPV congress is the forum where all PV stakeholders from all over the world meet and exchange ideas.
ANNUAL EUPV BOOKLET
The 3rd European Pharmacovigilance Congress: speaker abstracts 2019
The 4th European Pharmacovigilance Congress: speaker abstracts 2020
The 5th European Pharmacovigilance Congress: speaker abstracts 2021
The 6th European Pharmacovigilance Congress: speaker abstracts 2022
The 7th European Pharmacovigilance Congress: speaker abstracts 2023
Published by Sage Journals, visit their website here
Format del congresso
The European Pharmacovigilance Congress will be a mixed event!
18-19 November | Virtual 9 am- 6 pm
21 November | APERITIF TIME, NH Milano Congress Centre 6 pm – 9 pm
22 November | Face to face, NH Milano Congress Center 9.30 am – 5 pm
APERITIF TIME – November 21 from 6 to 9 pm – NH Milano Congress
Reserve your place to meet and network with your colleagues, experts and opinion leaders!
This year the congress will include:
– 25 Topics
– 11 Virtual & Face-to-Face Parallel Sessions
– 25 Interactives Round Tables
– 2 Face to-Face Workshops
– 2 LECTIO Magistralis
Perchè partecipare?
- Learn about the latest Pharmacovigilance trends and updates
- Share experiences and solutions at a leading European event
- Forge new collaborations with key decision makers
- Networking through the virtual platform with Pharma Companies Delegates and Speakers
A chi è rivolto?
- Pharma, Biotech and Medical Devices Industries
- Pharmacovigilance Associations
- Regulatory Bodies
- CROs and CMOs
- Clinical Research Sites
- Data Management Companies
- Software Development Companies
- University Faculties
- PV Consultant Societies
TOPICS 2024
THEMATIC SESSIONS
18/11 – Virtual
– Biological Basis of Adverse Reactions (with focus on SCARs)
– Immunological Adverse Reactions
– Parallel– Comunicating Safety Information in the Digital Era (in progress)
– Signal Detection
– Parallel – tbd
– Risk Management
– Parallel– Drug Safety in Marketing Authorization Applications (in progress)
– LECTIO Magistralis
19/11 – Virtual
– Authorities’ Assessment of PV Reports
– Real Word Data & Real Word Evidence
– Parallel – Evolving Landscape of Electronic Safety data in PV
– Manufacturing & PV Interfaces
– Parallel – Safety in Clinical Trials
– MedDRA (in progress)
– Parallel – Non EU PV Requirements
– LECTIO Magistralis
22/11 – Milan
– Evolving Pharmacovigilance Strategies
– Main Global and Local PV Updates
– Practical Experience of Applying Artificial Intelligence in PV
– Audit & Inspections
and more parallel sessions coming…
November 18th 2024, Virtual
09.00 – Marco Sardella, Chief Pharmacovigilance Officer & EU QPPV | ADIENNE Pharma & Biotech
09.10 – Arduino Mangoni, Strategic Professor in Clinical
Pharmacology | Flinders University, Senior Consultant in Clinical Pharmacology and General Medicine, Adelaide, Australia
09.15 – Chair – Giovanni Furlan, Worldwide Safety Site Lead – Thessaloniki (Greece), Safety Risk Lead, Director | Pfizer S.r.l.
09.20 – Arduino Mangoni, Strategic Professor in Clinical
Pharmacology | Flinders University, Senior Consultant in Clinical Pharmacology and General Medicine, Adelaide, Australia
09.40 – Chia-Yu Chu | Prof. Department of Dermatology | National Taiwan University
10.00 – Georgios Papazisis | Professor of Clinical Pharmacology; Medical Director, Clinical Research Unit, School of Medicine | Aristotle University of Thessaloniki, Greece
10.20 – Round Table and Q&A Time
Moderator: G. Furlan
Panelists: A. Mangoni; C. Y. Chu; G. Papazisis
10.50 – Coffee Break & networking
11.10 – Chair – Mattia Calissano | Head of Pharmacovigilance | Orchard Therapeutics
11.15 – Anne de Groot | CEO/CSO and Director | EpiVax
11.35 – Amy Rosenberg | Senior Director and Consultant, Immunology | EpiVax, Inc
11.55 – Round Table
Moderator: M. Calissano
Panelists: A. De Groot; A. Rosenberg
12.30 – LUNCH
11.10 – Chair – Paola Kruger, Head of Expert Patient | EUPATI (Europe an Patient’s Academy for Therapeutic Innovation)
11.20 – Safety Communication aspects of the ConcePTION Mobile App
Amanda Alexe | PV Policy and Liaison Lead, QPPV Office | Novartis
11.40 – Marco Greco, European Patients’ Forum President (EPF) – TBC
12.00 – Panel Discussion
12.30 – LUNCH
1.45 – Chair – Maddalena Lino, Safety Risk Lead Director | Pfizer
1.50 – Multi-modal data science for signal detection – What are the Challenges? What are the Opportunities?
Natsiavas Pantelis | Researcher (Grade C) | Institute of Applied Biosciences of Centre for Research and Technology Hellas (INAB|CERTH), Thessaloniki, Greece
2.10 – What is the role of Big Data and Artificial Intelligence in Pharmacovigilance?
Gianluca Trifirò | Full Professor of Pharmacology Department of Diagnostics and Public Health | University of Verona
2.30 – Insights into recent safety observations associated with CART cell therapies
Vibha Jawa | Executive Director for Biotherapeutics Bioanalysis in clinical Pharmacology, Pharmacometricsand Bioanalysis (NDB) organization | Bristol Myers Squibb
2.50 – Round Table and Q&A Time:
Moderator: M. Lino
Panelists: N. Pantelis; G. Trifirò; V. Jawa
3.20 – Coffee Break & Networking
3.40 – Chair – Glyn Belcher, CEO | PV Consultancy Ltd.
3.45 – Proposing Benefit-Risk Management Plans as the evolution of RMPs
Robert Massouh | Head of (PV) Risk Management and Benefit Risk Evaluation | Gsk
4.05 – Pregnancy prevention – RMM effectiveness evaluation experience
Klaudija Marijanovic Barac | Sr. Director, EU&UK QPPV Deputy, Head Periodic Reports and Risk Management Unit | TEVA
4.25 – Pharmaceuticals in the environment: from Echopharmacovigilance to neurobehavioral studieson zebrafish
Giovanna Paolone | Associate Professor of Pharmacology – Department of Diagnostics and Public Health | University of Verona
4.45 – Round Table and Q&A Time
Moderator: G. Belcher
Panelists: R. Massouh; K.M. Barac; G. Paolone
3.40 – Chair – Hrvoje Macek, VP, Medical & Scientific Affairs, an Patient’s Academy for Therapeutic Innovation
3.45 – Michael Von Forstner, Head of Safety Science | Sobi
4.05 – From assessment of ADR reports to risk minimisation measures (RMM) implementation
Morana Pavičić, Principal Coordinator of the National ADR Centre and Pharmacoepidemiology Pharmacovigilance and Rational Pharmacotherapy Departement | HALMED
4.25 – Challenges of benefit-risk assessment – when to trigger a referral procedure?
Barbara Kovačić Bytyqi, Head of Departement for Pharmacovigilance and Rational Pharmacotherapy | HALMED
4.45 – Round Table and Q&A Time
Moderator: H. Macek
Panelists: B. Kovačić Bytyqi; M. Pavičić; M. Von Forstner
5.15 – Marco Sardella, Chief Pharmacovigilance Officer & EU QPPV | ADIENNE Pharma & Biotech
5.20 – Nicholas Moore | Emeritus Professor of Clinical Pharmacology | University of Bordeaux
5.45 – Q&A Time
6.00 – Closure of the Day
November 19th 2024, Virtual
09.00 – Marco Sardella, Chief Pharmacovigilance Officer & EU QPPV | ADIENNE Pharma & Biotech
09.10 – Chair – Mircea Ciuca, Global Therapeutic Area Head in Global Clinical Safety and Pharmacovigilance
09.15 – John Joseph Borg | Director Post-Licensing | Malta
Medicines Authority
09.35 – Roxana Dondera | Head of Pharmacovigilance and Risk Management Unit | National Agency for Medicine and Medical Devices of Romania
09.55 – Sofia Trantza | Senior Pharmacovigilance Expert | PRAC member Greece
10.15 – Round Table and Q&A Time
Moderator: M. Ciuca
Panelists: J.J. Borg; R. Dondera; S. Trantza
10.45 – Coffee Break & networking
11.05 – Chair – Lembit Rago | Secretary-General |Council for International Organizations of Medical Sciences (CIOMS)
11.10 – RWD and RWE in regulatory decision making: CIOMS WG XIII Report
Lembit Rago | Secretary-General |Council for International Organizations of Medical Sciences (CIOMS)
11.30 – From RWD to RWE – Teva experience
Željana Margan Koletić | Senior Manager, Risk Management Plans (RMP) Team Leader | Teva
11.50 – Analysis of the nature and contributory factors of medication safety incidents following Hospital disharge using National Reporting and Learning System (NRLS) data from England and Wales: a multi-method study
Fatema Alqenae | Pharmacist | Kuwait – Winner EUPV 2023 Award
12.10 – Round Table and Q&A Time
Moderator: L. Rago
Panelists: Z.M. Koletic; F. Alqenae
12.30 – LUNCH
11.05 – Chair – Jan Petracek, CEO | iVigee
11.10 – Calin Lungu | DDCS S.A., CEO
11.40 – TBD
12.00 – Panel Discussion
12.30 – LUNCH
1.45 – Chair – Valentina Mancini, Senior Director Pharmacovigilance QPPV | Shionogi Europe
1.50 – AIFA Representative (tbc)
2.10 – NCE Early Development and Manufacturing : Idiosyncratic Reactions Risk Mitigation in Post Marketing
Terenzio Ignoni | SVP Quality and CMC | Gain Therapeutics
2.30 – Impact of Manufacturing Changes on Pharmacovigilance for Biological Products
Dina B. Tresnan | Disease Area Cluster Lead – Immunolo-Oncology; Safety Surveillance and Risk Management, Worldwide Safety | Pfizer
2.50 – Round Table
Moderator: TBC
Panelists: AIFA Representative (tbc); T. Ignoni; D. Tresnan; V. Mancini
1.45 – Chair – TBD
1.50 – A Fresh Approach to Development Safety Update Reports/Annual Safety Reports
Maria Beatrice Panico, Principal Consultant | Scendea
2.10 – In Progress…
3.20 – Coffee Break
3.40 – Chair – Marco Sardella, Chief Pharmacovigilance Officer & EU QPPV | ADIENNE Pharma & Biotech
3.45 – Adverse Event Grouping Strategies During Clinical Trial Analysis
Scott Proestel | Senior Medical Officer | FDA
4.05 – Aoibhinn McDonnell, Safety Risk Lead, Director, Safety Surveillance and Risk Management | Pfizer
4.25 – Round Table
Moderator: M. Sardella
Panelists: S. Proestel; A. McDonnell
3.40 – Chair – Mattia Calissano, Head of Pharmacovigilance | Orchard Therapeutics
3.45 – UK Pharmacovigilance Requirements: A Regulator’s Perspective
Fazil Afzal | Medical Assessor at Medicines and Healthcare products Regulatory Agency (tbc)
4.05 – Elevating Pharmacovigilance in Saudi Arabia beyond Benchmarks to Innovation
Mayssa Abou Ghannam | Country Safety Team Lead, Saudi Arabia, Gulf, Pakistan, Afghanistan | Johnson & Johnson
4.25 – Comparison of RMM Approaches across EU, Japan and US
Robert Massouh | Head of (PV) Risk Management and Benefit Risk Evaluation | Gsk
4.45 – Regulatory Requirements of Pharmacovigilance in India
Geeta Shanbhag | VP Pharmacovigilance and MedicoRegulatory Affairs | Ipca Laboratories Ltd.
5.05 – Round Table
Moderator: M. Calissano
Panelists: F. Afzal; M. AbouGhannam; R. Massouh; G. Shanbhag
5.30 – Marco Sardella, Chief Pharmacovigilance Officer & EU QPPV | ADIENNE Pharma & Biotech
5.30 – Pharmacovigilance – Where have we come from and where are we going?
Glyn Belcher | Senior Scientific Advisor | EUPV Congress
6.00 Closure of the Day
November 22nd, Face-to-Face in Milan
09.20 – Marco Sardella, Chief Pharmacovigilance Officer & EU QPPV | ADIENNE Pharma & Biotech
9.30 – Chair of the Session
Giovanni Furlan | Worldwide Safety Site Lead – Thessaloniki (Greece), Safety Risk Lead, Director | Pfizer S.r.l.
Panel Discussion:
Felix Arellano | Senior Vice President and the Global Head of Safety & Risk Management | Roche
Andrew Bate | VP Safety Innovation & Analytics | GSK
Marcin Kruk | Drug Safety Regional Head Europe , Africa, Middle East, Worlwide Medical & Safety | Pfizer Inc.
Sofia Trantza | Senior Pharmacovigilance Expert |
PRAC Member Greece
10.40 – Coffee Break
11.10 – Chair of the Session
Calin Lungu | DDCS S.A., CEO
11.15 – AIFA Representative (tbc)
11.35 – Global and Local PV Regulatory Intelligence with AI: New Collection, Assessment, and Interpretation
Marcela Fialova | Chief Operating Officer | iVigee
11.55 – Ilaria Grisoni | Exec. Dir., Head of EU/International PV & Office of QPPV, EEA QPPV | Jazz Pharmaceuticals
12.15 – Round Table
Moderator: C. Lungu
Panelists: AIFA Representative; I. Grisoni; M. Fialova; D. Marcozzi
12.40 – Award Ceremony for the selected PV article published in Therapeutic Advanced in Drug Safety 2023
12.50 – Lunch & Networking
2.00 – Chair – Andrew Bate | VP Safety Innovation & Analytics | GSK
2.05 – MHRA experience in applications for AI in Pharmacovigilance
Phil Tregunno | Deputy Director, Patient Safety Monitoring, Safety and Surveillance | MHRA
2.25 – Revolutionize Signal management with AI
Maurizio Sessa | Associate Professor of Pharmacoepidemiology | University of Copenhagen
2.45 – AI in Pharmacovigilance at the Swedish Medical products Agency
Gabriel Westman | Head of Artificial Intelligence | Swedish Medical Products Agency
3.05 – Round Table
Moderator: A. Bate
Panelists: P. Tregunno; M. Sessa; V. Mancini
3.30 – Coffee Break
4.00 – Chair – Gian Nicola Castiglione | Pharmacovigilance Senior Consultant, Member and Secretary of SIMeF, ETS Board, Master of Labor. Past Head of Global Pharmacovigilance and EU-UK QPPV | Chiesi Farmaceutici S.p.A.
4.05 – AIFA Representative (tbc)
4.25 – Mônica da Luz Carvalho | Health Regulatory Expert, Pharmacovigilance Adviser | Brazilian Health Surveillance Agency (ANVISA)
4.45 – Iva Novak | Head of European Pharmacovigilance and EU QPPV | Teva
5.05 – Round Table
Moderator: G.N. Catiglione
Panelists: AIFA Representative; M. D’Antuono; I. Novak; m. De Luz Carvalho
5.30 – Closure of the Congress
Scientific Advisory Group 2024 – In Progress…
Andrew Bate
VP, Head of Safety Innovation & Analytics | GSK
Glyn Belcher
Senior Scientific Advisor | EU PV
Congress
Mattia Calissano
Head of Pharmacovigilance | Orchard Therapeutics
Gian Nicola Castiglione
Pharmacovigilance Senior Consultant, Member and Secretary of SIMeF, ETS Board, Master of Labor. Past Head of Global Pharmacovigilance and EU-UK QPPV | Chiesi Farmaceutici S.p.A.
Mircea Ciuca
Global Therapeutic Area Head in Global Clinical Safety and Pharmacovigilance
Giovanni Furlan
Worldwide Safety Site Lead – Thessaloniki (Greece), Safety Risk Lead, Director | Pfizer S.r.l.
Calin A. Lungu
DDCS S.A., CEO
Hrvoje Maček
VP, Medical & Scientific Affairs, EU QPPV | PrimeVigilance
Valentina Mancini
Senior Director Pharmacovigilance, QPPV | Shionogi Europe
Jan Petracek
CEO | iVigee
Director, Institute of Pharmacovigilance
Marco Sardella
Chief Pharmacovigilance Officer & EU-UK QPPV| ADIENNE Pharma & Biotech
Speakers 2024 – In Progress…
John -Joseph Borg
Director Post-Licensing | Malta Medicines Authority
Roxana Dondera
Head of Pharmacovigilance and Risk Management Unit | National Agency for Medicine and Medical Devices of Romania
Fazil Afzal
Medical Assessor | Medicines and Healthcare products Regulatory Agency (MHRA)
Felix Arellano
Senior Vice President and the Global Head of Safety & Risk Management | Roche
Phil Tregunno
Deputy Director, Patient Safety Monitoring, Safety and Surveillance | MHR
Scott Proestel
Senior Medical Officer | FDA (tbc)
Andrew Bate
VP Safety Innovation & Analytics | GSK
Lembit Rägo
Secretary-General | Council for International Organizations of Medical Sciences (CIOMS)
Glyn Belcher
Senior Scientific Advisor | EU PV Congress
Calin A. Lungu
DDCS S.A., CEO
Sofia Trantza
Senior Pharmacovigilance Expert , PRAC member Greece
Arduino Mangoni
Strategic Professor in Clinical Pharmacology | Flinders University; Senior Consultant in Clinical Pharmacology and General Medicine, Adelaide, Australia
Terenzio Ignoni
SVP Quality and CMC | Gain Therapeutics
Gabriel Westman
Head of Artificial Intelligence | Swedish Medical Products Agency
Anne De Groot
CEO/CSO and Director | Epivax
Robert Massouh
Head of (PV) Risk Management and Benefit Risk Evaluation | Gsk
Nicholas Moore
Emeritus Professor of Clinical Pharmacology | University of Bordeaux
Chia Yu Chu
Prof. Department of Dermatology | National Taiwan University
Georgios Papazisis
Professor of Clinical Pharmacology; Medical Director, Clinical Research Unit | School of Medicine, Aristotle University of Thessaloniki
Marcin Kruk
Drug Safety Regional Head Europe , Africa, Middle East, Worlwide Medical & Safety |Pfizer Inc.
Mayssa AbouGhannam
Country Safety Team Lead, Saudi Arabia, Gulf, Pakistan, Afghanistan | Johnson & Johnson
Maria Beatrice Panico
Principal Consultant | Scendea
Maurizio Sessa
Associate Professor of Pharmacoepidemiology | University of Copenhagen
Amy Rosemberg
Senior Director and Consultant, Immunology | EpiVax, Inc
Geeta Shanbhag
VP Pharmacovigilance and Medico-Regulatory Affairs | Ipca Laboratories Ltd
Giovanna Paolone
Associate Professor of Pharmacology – Department of Diagnostics and Public Health | University of Verona
Alqenae Fatema
Pharmacist | University of Manchester –
Winner EUPV 2024 Award
Dina B. Tresnan
Disease Area Cluster Lead -Immunolo-Oncology; Safety
Surveillance and Risk Management, Worldwide Safety | Pfizer
Ilaria Grisoni
Executive Director, Head of EU/International PV & Office of QPPV, EEA QPPV | Jazz Pharmaceuticals
Vibha Jawa
Executive Director | Bristol Myers Squibb
Klaudija Marijanovic Barac
Sr. Director, EU&UK QPPV Deputy, Head Periodic Reports and Risk Management Centre | TEVA
Zeljana Margan Koletic
Senior Manager, Risk Management Plans (RMP) Team Leader | Teva
Iva Novak
Head of European Pharmacovigilance and EU QPPV | Teva
Marcela Fialova
Chief Operating Officer | iVigee
Margherita D’Antuono
EU-UK QPPV| Piramal Critical Care
Mônica da Luz Carvalho
Health Regulatory Expert, Pharmacovigilance Adviser | Brazilian Health Surveillance Agency (Anvisa)
Mario Greco
European Patients’ Forum President (EPF)
Maddalena Lino
Safety Risk Lead Director | Pfizer
Daniela Marcozzi
Head of Corporate Clinical Safety, Pharmacovigilance and R&D Compliance QP for Pharmacovigilance EU & UK, Graduated Plan Officer AMG 63a
Company Representative for Competent Health Authorities
Barbara Kovačić Bytyqi
Head of Department for Pharmacovigilance and Rational Pharmacotherapy | HALMED
Paola Kruger
Expert Patient | EUPATI (European Patient’s Academy for Therapeutic Innovation)
Morana Pavičić
Principal Coordinator of the National ADR Centre and Pharmacoepidemiology Pharmacovigilance and Rational Pharmacitherapy Department | HALMED
Michael Von Forstner
Head of Safety Science| Sobi
Iva Galic
Pharmacovigilance Inspector Expert | HALMED
Amalia Alexe
PV Policy and Liaison Lead, QPPV Office | Novartis
Sponsors & Media Partners 2024 – In Progress…
Insuvia
Bronze Sponsor
Insuvia
Bronze Sponsor
Insuvia is designed to act as a pharmacovigilance unit for pharmaceutical companies in those countries and regions, where they have no internal structures or decide to focus their resources on commercial activities. In this context, we provide the regional EU and country-level expertise to solve all pharmacovigilance challenges that pharmaceutical companies encounter while commercializing their products.
Visita il sito »
iVigee
Gold Plus Sponsor
iVigee
Gold Plus Sponsor
iVigee is a leading pharmacovigilance services and technology company focused on creating simple, powerful, and elegant drug safety solutions that span the entire drug safety life cycle.
We combine years of experience with the latest innovative AI technologies to create the ‘instant pharmacovigilance department’, deployable anywhere, on-demand.
Our teams support clients around the world with progressive pharmacovigilance and data management requirements from our strategic bases in Central Europe and the US East Coast.
iVigee: Simple. Powerful. Elegant.
Visita il sito »
Pharma D&S
Exhibitor
Pharma D&S
Exhibitor
Pharma D&S is an European Service Provider active in Lifescience field with a panel of more than 180 consultants who provide and support pharmaceutical companies in Pharmacovigilance, Clinical Research, Regulatory Affairs and Quality needs. We are partner whit over 400 companies by managing different areas of the product’s entire lifecycle and our customers can find a range of services and a multidisciplinary activities. We believe in the Relationship and client’s Loyalty, in understanding and sharing their goals, integrating with their staff and processes. We trust People, fostering their growth and promoting their commitment. We believe in Innovation and Creativity, in seeking constantly new approaches, ideas and solutions.
Visita il sito »
ProductLife Group
Exhibitor
ProductLife Group
Exhibitor
ProductLife Group’s mission is to improve human health by delivering regulatory compliance services for the safe and effective use of medical solutions.
Since 30 years, PLG supports clients through the entire product life cycle, combining local expertise with global reach spanning more than 150 countries. It provides consulting and outsourcing services in the areas of regulatory affairs, quality and compliance, market access, vigilances and medical information, covering both established products and innovative therapeutics & diagnostics.
With a goal of continuously improving the value delivered to people and customers, PLG is committed to long-term partnership, innovation, flexibility, and cost efficiency.
Visita il sito »
PrimeVigilance
Gold Sponsor
PrimeVigilance
Gold Sponsor
PrimeVigilance, an Ergomed company, has grown to become the leading Pharmacovigilance specialist company, delivering global solutions for clinical safety and post-marketing pharmacovigilance and medical information from our operational hubs based in Europe, the USA, and Japan.
Our extensive experience enables us to offer a comprehensive, top-quality, cost-effective, and innovative safety solution. Our flexible approach, tailor-made to work with clients, allows us to deliver the services that meet your clinical and post-marketing needs.
PrimeVigilance provides pharmacovigilance solutions to over 200 clients who distribute their products worldwide. PrimeVigilance manages a global Pharmacovigilance system with a choice of leading drug safety databases stretching to more than 100 countries.
Visita il sito »
Sage
Media Partner
Sage
Media Partner
Published by SAGE, Therapeutic Advances in Drug Safety (Impact Factor: 4.4) is an international peer-reviewed Open Access journal, delivering the highest quality original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in drug safety, providing an online forum for rapid dissemination of recent research and perspectives in this area.
As the official Media Partner of the 6th edition of the European Pharmacovigilance Congress, Therapeutic Advances in Drug Safety will be publishing an online abstract supplement which will be free to access online.
For more information:
E-mail: jonathan.collin@sagepub.co.uk
Twitter: @TADrugSafety
Visita il sito »
Max Application
Exhibitor
Max Application
Exhibitor
Max Application is an IT company specialized in software solutions and focused on continuity, competence and passion in service.
Oracle partner for over 20 years, it offers cloud and on-premise solutions for sectors such as textile manufacturing, automotive and in mainly healthcare. The flagship of the latter is SafetyDrugs, the leading safety database for pharmacovigilance in Italy, accompanied by the Business Intelligence module, essential for Signal Detection.
Always committed to innovation, now part of Abacus Group, it benefits from the synergies and opportunities offered by this strategic partnership in areas such as IT infrastructure, cybersecurity, system integration and artificial intelligence.
Visita il sito »
Diventa sponsor
The European Pharmacovigilance Congress provides an excellent opportunity to get in touch with PV professionals and decision makers through a powerful virtual exhibition area. To sponsor the event, contact us.
Sede del congresso
Step 1
On November 18-19 the event will be VIRTUAL to grant you the possibility of joining the conference even from your office or home, wherever you may be. We have organized a true virtual location, a space where you will be able to:
- Follow the live streaming of the congress, listen to experts and opinion makers and be informed about latest trends and technological breakthroughs in drug safety
- Visit the VIRTUAL EXHIBITION AREA and all the stands of our sponsors
- Join Q&A times and round tables to discuss the current hot topics in the field
- Chat with our sponsors and learn about new technologies and services to ease your daily work and increase the performance
Step 2
Let’s finally meet face to face in Milan on November 22! A great chance to meet in person the EUPV experts and colleagues. A great chance to meet in person the EUPV experts and colleagues. The conference will be hosted in the wonderful spaces of NH Milano Congress Centre, in Assago, Milan.
Panoramica della conferenza
The European Pharmacovigilance Congress, organized by Pharma Education Center, is recognized as one of the most important and appreciated global pharmacovigilance conferences.
EUPV congress is proud to have high quality scientific content as its main characteristic which has attracted growing interest from speakers, sponsors and participants from all over the world.
The EUPV congress gathers PV professionals at all career levels, including key decision makers (e.g. VPs, Executives and Directors,) interested in the always evolving pharmacovigilance world and its new trends, since they are always looking for new ideas to implement more efficient and effective strategies and tools for their departments.
To further improve the value of the congress and continuously make it more and more interesting by bringing new ideas and scientific contents, this year the Scientific Advisory Group has been further widened with the addition of new PV key opinion leaders who need no introduction since their knowledge and skills are world class.
EUPV congress is the forum where all PV stakeholders from all over the world meet and exchange ideas.
ANNUAL EUPV BOOKLET
The 3rd European Pharmacovigilance Congress: speaker abstracts 2019
The 4th European Pharmacovigilance Congress: speaker abstracts 2020
The 5th European Pharmacovigilance Congress: speaker abstracts 2021
The 6th European Pharmacovigilance Congress: speaker abstracts 2022
The 7th European Pharmacovigilance Congress: speaker abstracts 2023
Published by Sage Journals, visit their website here
Format del congresso
The European Pharmacovigilance Congress will be a mixed event!
18-19 November | Virtual 9 am- 6 pm
21 November | APERITIF TIME, NH Milano Congress Centre 6 pm – 9 pm
22 November | Face to face, NH Milano Congress Center 9.30 am – 5 pm
APERITIF TIME – November 21 from 6 to 9 pm – NH Milano Congress
Reserve your place to meet and network with your colleagues, experts and opinion leaders!
This year the congress will include:
– 25 Topics
– 11 Virtual & Face-to-Face Parallel Sessions
– 25 Interactives Round Tables
– 2 Face to-Face Workshops
– 2 LECTIO Magistralis
Perchè partecipare?
- Learn about the latest Pharmacovigilance trends and updates
- Share experiences and solutions at a leading European event
- Forge new collaborations with key decision makers
- Networking through the virtual platform with Pharma Companies Delegates and Speakers
A chi è rivolto?
- Pharma, Biotech and Medical Devices Industries
- Pharmacovigilance Associations
- Regulatory Bodies
- CROs and CMOs
- Clinical Research Sites
- Data Management Companies
- Software Development Companies
- University Faculties
- PV Consultant Societies
TOPICS 2024
THEMATIC SESSIONS
18/11 – Virtual
– Biological Basis of Adverse Reactions (with focus on SCARs)
– Immunological Adverse Reactions
– Parallel– Comunicating Safety Information in the Digital Era (in progress)
– Signal Detection
– Parallel – tbd
– Risk Management
– Parallel– Drug Safety in Marketing Authorization Applications (in progress)
– LECTIO Magistralis
19/11 – Virtual
– Authorities’ Assessment of PV Reports
– Real Word Data & Real Word Evidence
– Parallel – Evolving Landscape of Electronic Safety data in PV
– Manufacturing & PV Interfaces
– Parallel – Safety in Clinical Trials
– MedDRA (in progress)
– Parallel – Non EU PV Requirements
– LECTIO Magistralis
22/11 – Milan
– Evolving Pharmacovigilance Strategies
– Main Global and Local PV Updates
– Practical Experience of Applying Artificial Intelligence in PV
– Audit & Inspections
and more parallel sessions coming…
November 18th 2024, Virtual
09.00 – Marco Sardella, Chief Pharmacovigilance Officer & EU QPPV | ADIENNE Pharma & Biotech
09.10 – Arduino Mangoni, Strategic Professor in Clinical
Pharmacology | Flinders University, Senior Consultant in Clinical Pharmacology and General Medicine, Adelaide, Australia
09.15 – Chair – Giovanni Furlan, Worldwide Safety Site Lead – Thessaloniki (Greece), Safety Risk Lead, Director | Pfizer S.r.l.
09.20 – Arduino Mangoni, Strategic Professor in Clinical
Pharmacology | Flinders University, Senior Consultant in Clinical Pharmacology and General Medicine, Adelaide, Australia
09.40 – Chia-Yu Chu | Prof. Department of Dermatology | National Taiwan University
10.00 – Georgios Papazisis | Professor of Clinical Pharmacology; Medical Director, Clinical Research Unit, School of Medicine | Aristotle University of Thessaloniki, Greece
10.20 – Round Table and Q&A Time
Moderator: G. Furlan
Panelists: A. Mangoni; C. Y. Chu; G. Papazisis
10.50 – Coffee Break & networking
11.10 – Chair – Mattia Calissano | Head of Pharmacovigilance | Orchard Therapeutics
11.15 – Anne de Groot | CEO/CSO and Director | EpiVax
11.35 – Amy Rosenberg | Senior Director and Consultant, Immunology | EpiVax, Inc
11.55 – Round Table
Moderator: M. Calissano
Panelists: A. De Groot; A. Rosenberg
12.30 – LUNCH
11.10 – Chair – Paola Kruger, Head of Expert Patient | EUPATI (Europe an Patient’s Academy for Therapeutic Innovation)
11.20 – Safety Communication aspects of the ConcePTION Mobile App
Amanda Alexe | PV Policy and Liaison Lead, QPPV Office | Novartis
11.40 – Marco Greco, European Patients’ Forum President (EPF) – TBC
12.00 – Panel Discussion
12.30 – LUNCH
1.45 – Chair – Maddalena Lino, Safety Risk Lead Director | Pfizer
1.50 – Multi-modal data science for signal detection – What are the Challenges? What are the Opportunities?
Natsiavas Pantelis | Researcher (Grade C) | Institute of Applied Biosciences of Centre for Research and Technology Hellas (INAB|CERTH), Thessaloniki, Greece
2.10 – What is the role of Big Data and Artificial Intelligence in Pharmacovigilance?
Gianluca Trifirò | Full Professor of Pharmacology Department of Diagnostics and Public Health | University of Verona
2.30 – Insights into recent safety observations associated with CART cell therapies
Vibha Jawa | Executive Director for Biotherapeutics Bioanalysis in clinical Pharmacology, Pharmacometricsand Bioanalysis (NDB) organization | Bristol Myers Squibb
2.50 – Round Table and Q&A Time:
Moderator: M. Lino
Panelists: N. Pantelis; G. Trifirò; V. Jawa
3.20 – Coffee Break & Networking
3.40 – Chair – Glyn Belcher, CEO | PV Consultancy Ltd.
3.45 – Proposing Benefit-Risk Management Plans as the evolution of RMPs
Robert Massouh | Head of (PV) Risk Management and Benefit Risk Evaluation | Gsk
4.05 – Pregnancy prevention – RMM effectiveness evaluation experience
Klaudija Marijanovic Barac | Sr. Director, EU&UK QPPV Deputy, Head Periodic Reports and Risk Management Unit | TEVA
4.25 – Pharmaceuticals in the environment: from Echopharmacovigilance to neurobehavioral studieson zebrafish
Giovanna Paolone | Associate Professor of Pharmacology – Department of Diagnostics and Public Health | University of Verona
4.45 – Round Table and Q&A Time
Moderator: G. Belcher
Panelists: R. Massouh; K.M. Barac; G. Paolone
3.40 – Chair – Hrvoje Macek, VP, Medical & Scientific Affairs, an Patient’s Academy for Therapeutic Innovation
3.45 – Michael Von Forstner, Head of Safety Science | Sobi
4.05 – From assessment of ADR reports to risk minimisation measures (RMM) implementation
Morana Pavičić, Principal Coordinator of the National ADR Centre and Pharmacoepidemiology Pharmacovigilance and Rational Pharmacotherapy Departement | HALMED
4.25 – Challenges of benefit-risk assessment – when to trigger a referral procedure?
Barbara Kovačić Bytyqi, Head of Departement for Pharmacovigilance and Rational Pharmacotherapy | HALMED
4.45 – Round Table and Q&A Time
Moderator: H. Macek
Panelists: B. Kovačić Bytyqi; M. Pavičić; M. Von Forstner
5.15 – Marco Sardella, Chief Pharmacovigilance Officer & EU QPPV | ADIENNE Pharma & Biotech
5.20 – Nicholas Moore | Emeritus Professor of Clinical Pharmacology | University of Bordeaux
5.45 – Q&A Time
6.00 – Closure of the Day
November 19th 2024, Virtual
09.00 – Marco Sardella, Chief Pharmacovigilance Officer & EU QPPV | ADIENNE Pharma & Biotech
09.10 – Chair – Mircea Ciuca, Global Therapeutic Area Head in Global Clinical Safety and Pharmacovigilance
09.15 – John Joseph Borg | Director Post-Licensing | Malta
Medicines Authority
09.35 – Roxana Dondera | Head of Pharmacovigilance and Risk Management Unit | National Agency for Medicine and Medical Devices of Romania
09.55 – Sofia Trantza | Senior Pharmacovigilance Expert | PRAC member Greece
10.15 – Round Table and Q&A Time
Moderator: M. Ciuca
Panelists: J.J. Borg; R. Dondera; S. Trantza
10.45 – Coffee Break & networking
11.05 – Chair – Lembit Rago | Secretary-General |Council for International Organizations of Medical Sciences (CIOMS)
11.10 – RWD and RWE in regulatory decision making: CIOMS WG XIII Report
Lembit Rago | Secretary-General |Council for International Organizations of Medical Sciences (CIOMS)
11.30 – From RWD to RWE – Teva experience
Željana Margan Koletić | Senior Manager, Risk Management Plans (RMP) Team Leader | Teva
11.50 – Analysis of the nature and contributory factors of medication safety incidents following Hospital disharge using National Reporting and Learning System (NRLS) data from England and Wales: a multi-method study
Fatema Alqenae | Pharmacist | Kuwait – Winner EUPV 2023 Award
12.10 – Round Table and Q&A Time
Moderator: L. Rago
Panelists: Z.M. Koletic; F. Alqenae
12.30 – LUNCH
11.05 – Chair – Jan Petracek, CEO | iVigee
11.10 – Calin Lungu | DDCS S.A., CEO
11.40 – TBD
12.00 – Panel Discussion
12.30 – LUNCH
1.45 – Chair – Valentina Mancini, Senior Director Pharmacovigilance QPPV | Shionogi Europe
1.50 – AIFA Representative (tbc)
2.10 – NCE Early Development and Manufacturing : Idiosyncratic Reactions Risk Mitigation in Post Marketing
Terenzio Ignoni | SVP Quality and CMC | Gain Therapeutics
2.30 – Impact of Manufacturing Changes on Pharmacovigilance for Biological Products
Dina B. Tresnan | Disease Area Cluster Lead – Immunolo-Oncology; Safety Surveillance and Risk Management, Worldwide Safety | Pfizer
2.50 – Round Table
Moderator: TBC
Panelists: AIFA Representative (tbc); T. Ignoni; D. Tresnan; V. Mancini
1.45 – Chair – TBD
1.50 – A Fresh Approach to Development Safety Update Reports/Annual Safety Reports
Maria Beatrice Panico, Principal Consultant | Scendea
2.10 – In Progress…
3.20 – Coffee Break
3.40 – Chair – Marco Sardella, Chief Pharmacovigilance Officer & EU QPPV | ADIENNE Pharma & Biotech
3.45 – Adverse Event Grouping Strategies During Clinical Trial Analysis
Scott Proestel | Senior Medical Officer | FDA
4.05 – Aoibhinn McDonnell, Safety Risk Lead, Director, Safety Surveillance and Risk Management | Pfizer
4.25 – Round Table
Moderator: M. Sardella
Panelists: S. Proestel; A. McDonnell
3.40 – Chair – Mattia Calissano, Head of Pharmacovigilance | Orchard Therapeutics
3.45 – UK Pharmacovigilance Requirements: A Regulator’s Perspective
Fazil Afzal | Medical Assessor at Medicines and Healthcare products Regulatory Agency (tbc)
4.05 – Elevating Pharmacovigilance in Saudi Arabia beyond Benchmarks to Innovation
Mayssa Abou Ghannam | Country Safety Team Lead, Saudi Arabia, Gulf, Pakistan, Afghanistan | Johnson & Johnson
4.25 – Comparison of RMM Approaches across EU, Japan and US
Robert Massouh | Head of (PV) Risk Management and Benefit Risk Evaluation | Gsk
4.45 – Regulatory Requirements of Pharmacovigilance in India
Geeta Shanbhag | VP Pharmacovigilance and MedicoRegulatory Affairs | Ipca Laboratories Ltd.
5.05 – Round Table
Moderator: M. Calissano
Panelists: F. Afzal; M. AbouGhannam; R. Massouh; G. Shanbhag
5.30 – Marco Sardella, Chief Pharmacovigilance Officer & EU QPPV | ADIENNE Pharma & Biotech
5.30 – Pharmacovigilance – Where have we come from and where are we going?
Glyn Belcher | Senior Scientific Advisor | EUPV Congress
6.00 Closure of the Day
November 22nd, Face-to-Face in Milan
09.20 – Marco Sardella, Chief Pharmacovigilance Officer & EU QPPV | ADIENNE Pharma & Biotech
9.30 – Chair of the Session
Giovanni Furlan | Worldwide Safety Site Lead – Thessaloniki (Greece), Safety Risk Lead, Director | Pfizer S.r.l.
Panel Discussion:
Felix Arellano | Senior Vice President and the Global Head of Safety & Risk Management | Roche
Andrew Bate | VP Safety Innovation & Analytics | GSK
Marcin Kruk | Drug Safety Regional Head Europe , Africa, Middle East, Worlwide Medical & Safety | Pfizer Inc.
Sofia Trantza | Senior Pharmacovigilance Expert |
PRAC Member Greece
10.40 – Coffee Break
11.10 – Chair of the Session
Calin Lungu | DDCS S.A., CEO
11.15 – AIFA Representative (tbc)
11.35 – Global and Local PV Regulatory Intelligence with AI: New Collection, Assessment, and Interpretation
Marcela Fialova | Chief Operating Officer | iVigee
11.55 – Ilaria Grisoni | Exec. Dir., Head of EU/International PV & Office of QPPV, EEA QPPV | Jazz Pharmaceuticals
12.15 – Round Table
Moderator: C. Lungu
Panelists: AIFA Representative; I. Grisoni; M. Fialova; D. Marcozzi
12.40 – Award Ceremony for the selected PV article published in Therapeutic Advanced in Drug Safety 2023
12.50 – Lunch & Networking
2.00 – Chair – Andrew Bate | VP Safety Innovation & Analytics | GSK
2.05 – MHRA experience in applications for AI in Pharmacovigilance
Phil Tregunno | Deputy Director, Patient Safety Monitoring, Safety and Surveillance | MHRA
2.25 – Revolutionize Signal management with AI
Maurizio Sessa | Associate Professor of Pharmacoepidemiology | University of Copenhagen
2.45 – AI in Pharmacovigilance at the Swedish Medical products Agency
Gabriel Westman | Head of Artificial Intelligence | Swedish Medical Products Agency
3.05 – Round Table
Moderator: A. Bate
Panelists: P. Tregunno; M. Sessa; V. Mancini
3.30 – Coffee Break
4.00 – Chair – Gian Nicola Castiglione | Pharmacovigilance Senior Consultant, Member and Secretary of SIMeF, ETS Board, Master of Labor. Past Head of Global Pharmacovigilance and EU-UK QPPV | Chiesi Farmaceutici S.p.A.
4.05 – AIFA Representative (tbc)
4.25 – Mônica da Luz Carvalho | Health Regulatory Expert, Pharmacovigilance Adviser | Brazilian Health Surveillance Agency (ANVISA)
4.45 – Iva Novak | Head of European Pharmacovigilance and EU QPPV | Teva
5.05 – Round Table
Moderator: G.N. Catiglione
Panelists: AIFA Representative; M. D’Antuono; I. Novak; m. De Luz Carvalho
5.30 – Closure of the Congress
Scientific Advisory Group 2024 - In Progress...
Andrew Bate
VP, Head of Safety Innovation & Analytics | GSK
Glyn Belcher
Senior Scientific Advisor | EU PV
Congress
Mattia Calissano
Head of Pharmacovigilance | Orchard Therapeutics
Gian Nicola Castiglione
Pharmacovigilance Senior Consultant, Member and Secretary of SIMeF, ETS Board, Master of Labor. Past Head of Global Pharmacovigilance and EU-UK QPPV | Chiesi Farmaceutici S.p.A.
Mircea Ciuca
Global Therapeutic Area Head in Global Clinical Safety and Pharmacovigilance
Giovanni Furlan
Worldwide Safety Site Lead – Thessaloniki (Greece), Safety Risk Lead, Director | Pfizer S.r.l.
Calin A. Lungu
DDCS S.A., CEO
Hrvoje Maček
VP, Medical & Scientific Affairs, EU QPPV | PrimeVigilance
Valentina Mancini
Senior Director Pharmacovigilance, QPPV | Shionogi Europe
Jan Petracek
CEO | iVigee
Director, Institute of Pharmacovigilance
Marco Sardella
Chief Pharmacovigilance Officer & EU-UK QPPV| ADIENNE Pharma & Biotech
Speakers 2024 - In Progress...
John -Joseph Borg
Director Post-Licensing | Malta Medicines Authority
Roxana Dondera
Head of Pharmacovigilance and Risk Management Unit | National Agency for Medicine and Medical Devices of Romania
Fazil Afzal
Medical Assessor | Medicines and Healthcare products Regulatory Agency (MHRA)
Felix Arellano
Senior Vice President and the Global Head of Safety & Risk Management | Roche
Phil Tregunno
Deputy Director, Patient Safety Monitoring, Safety and Surveillance | MHR
Scott Proestel
Senior Medical Officer | FDA (tbc)
Andrew Bate
VP Safety Innovation & Analytics | GSK
Lembit Rägo
Secretary-General | Council for International Organizations of Medical Sciences (CIOMS)
Glyn Belcher
Senior Scientific Advisor | EU PV Congress
Calin A. Lungu
DDCS S.A., CEO
Sofia Trantza
Senior Pharmacovigilance Expert , PRAC member Greece
Arduino Mangoni
Strategic Professor in Clinical Pharmacology | Flinders University; Senior Consultant in Clinical Pharmacology and General Medicine, Adelaide, Australia
Terenzio Ignoni
SVP Quality and CMC | Gain Therapeutics
Gabriel Westman
Head of Artificial Intelligence | Swedish Medical Products Agency
Anne De Groot
CEO/CSO and Director | Epivax
Robert Massouh
Head of (PV) Risk Management and Benefit Risk Evaluation | Gsk
Nicholas Moore
Emeritus Professor of Clinical Pharmacology | University of Bordeaux
Chia Yu Chu
Prof. Department of Dermatology | National Taiwan University
Georgios Papazisis
Professor of Clinical Pharmacology; Medical Director, Clinical Research Unit | School of Medicine, Aristotle University of Thessaloniki
Marcin Kruk
Drug Safety Regional Head Europe , Africa, Middle East, Worlwide Medical & Safety |Pfizer Inc.
Mayssa AbouGhannam
Country Safety Team Lead, Saudi Arabia, Gulf, Pakistan, Afghanistan | Johnson & Johnson
Maria Beatrice Panico
Principal Consultant | Scendea
Maurizio Sessa
Associate Professor of Pharmacoepidemiology | University of Copenhagen
Amy Rosemberg
Senior Director and Consultant, Immunology | EpiVax, Inc
Geeta Shanbhag
VP Pharmacovigilance and Medico-Regulatory Affairs | Ipca Laboratories Ltd
Giovanna Paolone
Associate Professor of Pharmacology – Department of Diagnostics and Public Health | University of Verona
Alqenae Fatema
Pharmacist | University of Manchester –
Winner EUPV 2024 Award
Dina B. Tresnan
Disease Area Cluster Lead -Immunolo-Oncology; Safety
Surveillance and Risk Management, Worldwide Safety | Pfizer
Ilaria Grisoni
Executive Director, Head of EU/International PV & Office of QPPV, EEA QPPV | Jazz Pharmaceuticals
Vibha Jawa
Executive Director | Bristol Myers Squibb
Klaudija Marijanovic Barac
Sr. Director, EU&UK QPPV Deputy, Head Periodic Reports and Risk Management Centre | TEVA
Zeljana Margan Koletic
Senior Manager, Risk Management Plans (RMP) Team Leader | Teva
Iva Novak
Head of European Pharmacovigilance and EU QPPV | Teva
Marcela Fialova
Chief Operating Officer | iVigee
Margherita D'Antuono
EU-UK QPPV| Piramal Critical Care
Mônica da Luz Carvalho
Health Regulatory Expert, Pharmacovigilance Adviser | Brazilian Health Surveillance Agency (Anvisa)
Mario Greco
European Patients’ Forum President (EPF)
Maddalena Lino
Safety Risk Lead Director | Pfizer
Daniela Marcozzi
Head of Corporate Clinical Safety, Pharmacovigilance and R&D Compliance QP for Pharmacovigilance EU & UK, Graduated Plan Officer AMG 63a
Company Representative for Competent Health Authorities
Barbara Kovačić Bytyqi
Head of Department for Pharmacovigilance and Rational Pharmacotherapy | HALMED
Paola Kruger
Expert Patient | EUPATI (European Patient’s Academy for Therapeutic Innovation)
Morana Pavičić
Principal Coordinator of the National ADR Centre and Pharmacoepidemiology Pharmacovigilance and Rational Pharmacitherapy Department | HALMED
Michael Von Forstner
Head of Safety Science| Sobi
Iva Galic
Pharmacovigilance Inspector Expert | HALMED
Amalia Alexe
PV Policy and Liaison Lead, QPPV Office | Novartis
Sponsors & Media Partners 2024 - In Progress...
Insuvia
Bronze Sponsor
Insuvia
Bronze Sponsor
Insuvia is designed to act as a pharmacovigilance unit for pharmaceutical companies in those countries and regions, where they have no internal structures or decide to focus their resources on commercial activities. In this context, we provide the regional EU and country-level expertise to solve all pharmacovigilance challenges that pharmaceutical companies encounter while commercializing their products.
Visita il sito »
iVigee
Gold Plus Sponsor
iVigee
Gold Plus Sponsor
iVigee is a leading pharmacovigilance services and technology company focused on creating simple, powerful, and elegant drug safety solutions that span the entire drug safety life cycle.
We combine years of experience with the latest innovative AI technologies to create the ‘instant pharmacovigilance department’, deployable anywhere, on-demand.
Our teams support clients around the world with progressive pharmacovigilance and data management requirements from our strategic bases in Central Europe and the US East Coast.
iVigee: Simple. Powerful. Elegant.
Visita il sito »
Pharma D&S
Exhibitor
Pharma D&S
Exhibitor
Pharma D&S is an European Service Provider active in Lifescience field with a panel of more than 180 consultants who provide and support pharmaceutical companies in Pharmacovigilance, Clinical Research, Regulatory Affairs and Quality needs. We are partner whit over 400 companies by managing different areas of the product’s entire lifecycle and our customers can find a range of services and a multidisciplinary activities. We believe in the Relationship and client’s Loyalty, in understanding and sharing their goals, integrating with their staff and processes. We trust People, fostering their growth and promoting their commitment. We believe in Innovation and Creativity, in seeking constantly new approaches, ideas and solutions.
Visita il sito »
ProductLife Group
Exhibitor
ProductLife Group
Exhibitor
ProductLife Group’s mission is to improve human health by delivering regulatory compliance services for the safe and effective use of medical solutions.
Since 30 years, PLG supports clients through the entire product life cycle, combining local expertise with global reach spanning more than 150 countries. It provides consulting and outsourcing services in the areas of regulatory affairs, quality and compliance, market access, vigilances and medical information, covering both established products and innovative therapeutics & diagnostics.
With a goal of continuously improving the value delivered to people and customers, PLG is committed to long-term partnership, innovation, flexibility, and cost efficiency.
Visita il sito »
PrimeVigilance
Gold Sponsor
PrimeVigilance
Gold Sponsor
PrimeVigilance, an Ergomed company, has grown to become the leading Pharmacovigilance specialist company, delivering global solutions for clinical safety and post-marketing pharmacovigilance and medical information from our operational hubs based in Europe, the USA, and Japan.
Our extensive experience enables us to offer a comprehensive, top-quality, cost-effective, and innovative safety solution. Our flexible approach, tailor-made to work with clients, allows us to deliver the services that meet your clinical and post-marketing needs.
PrimeVigilance provides pharmacovigilance solutions to over 200 clients who distribute their products worldwide. PrimeVigilance manages a global Pharmacovigilance system with a choice of leading drug safety databases stretching to more than 100 countries.
Visita il sito »
Sage
Media Partner
Sage
Media Partner
Published by SAGE, Therapeutic Advances in Drug Safety (Impact Factor: 4.4) is an international peer-reviewed Open Access journal, delivering the highest quality original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in drug safety, providing an online forum for rapid dissemination of recent research and perspectives in this area.
As the official Media Partner of the 6th edition of the European Pharmacovigilance Congress, Therapeutic Advances in Drug Safety will be publishing an online abstract supplement which will be free to access online.
For more information:
E-mail: jonathan.collin@sagepub.co.uk
Twitter: @TADrugSafety
Visita il sito »
Max Application
Exhibitor
Max Application
Exhibitor
Max Application is an IT company specialized in software solutions and focused on continuity, competence and passion in service.
Oracle partner for over 20 years, it offers cloud and on-premise solutions for sectors such as textile manufacturing, automotive and in mainly healthcare. The flagship of the latter is SafetyDrugs, the leading safety database for pharmacovigilance in Italy, accompanied by the Business Intelligence module, essential for Signal Detection.
Always committed to innovation, now part of Abacus Group, it benefits from the synergies and opportunities offered by this strategic partnership in areas such as IT infrastructure, cybersecurity, system integration and artificial intelligence.
Visita il sito »
Diventa sponsor
The European Pharmacovigilance Congress provides an excellent opportunity to get in touch with PV professionals and decision makers through a powerful virtual exhibition area. To sponsor the event, contact us.
Sede del congresso
Step 1
On November 18-19 the event will be VIRTUAL to grant you the possibility of joining the conference even from your office or home, wherever you may be. We have organized a true virtual location, a space where you will be able to:
- Follow the live streaming of the congress, listen to experts and opinion makers and be informed about latest trends and technological breakthroughs in drug safety
- Visit the VIRTUAL EXHIBITION AREA and all the stands of our sponsors
- Join Q&A times and round tables to discuss the current hot topics in the field
- Chat with our sponsors and learn about new technologies and services to ease your daily work and increase the performance
Step 2
Let’s finally meet face to face in Milan on November 22! A great chance to meet in person the EUPV experts and colleagues. A great chance to meet in person the EUPV experts and colleagues. The conference will be hosted in the wonderful spaces of NH Milano Congress Centre, in Assago, Milan.
Iscriviti alla conferenza
Face-to-Face (22/11/24) |
400€ |
Virtual (18-19/11/24) |
600€ |
Virtual + Face to Face (18-19/11/24 e 22/11/24) |
750€ |
* Ospedali, università e liberi professionisti ottengono uno sconto del 40% da applicare ai prezzi pubblicati (gli sconti non sono cumulabili).